Filing Details
Skye Bioscience, Inc. (NASDAQ:SKYE) filed a Form 8-K with the Securities and Exchange Commission on August 14, 2026, disclosing a material event.
8k filedNASDAQ:SKYE
Skye Bioscience, Inc. (SKYE) Reports Material Event to SEC
Skye Bioscience, Inc. (NASDAQ:SKYE) filed a Form 8-K with the Securities and Exchange Commission on August 14, 2026, disclosing a material event.
At publication ·
What changed
Skye Bioscience, Inc. (NASDAQ:SKYE) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Skye Bioscience, Inc. (NASDAQ:SKYE) filed a Form 8-K with the SEC on August 14, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $0.50 with a market capitalization of $37.0 million.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Skye Bioscience, Inc.'s stock currently trades at $0.50 with a market capitalization of $37.0M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Skye Bioscience, Inc.'s stock.
All SEC filings for Skye Bioscience, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SKYE Stock Page
Frequently Asked Questions
Where can I read SKYE's SEC filings?
Browse all filings on our SKYE SEC filings page.
What types of SEC filings does Skye Bioscience, Inc. file?
Public companies like Skye Bioscience, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.